ASND Ascendis Pharma A/S

BULLISH Impact: 4/10 Insider Cluster (2 insiders)
Horizon weeks Filed Jun 2, 2026 Processed 2d 23h ago
Insider cluster: 2 insiders, $67K total

Price Chart

Loading chart...

Executive Summary

CFO Scott Thomas and Director Jean-Jacques Bienaimé made open-market purchases totaling $67K over a 5-day window. While the dollar amount is trivial relative to ASND's $13.6B market cap (0.0005%), cluster buys — especially involving C-suite — carry asymmetric informational weight per the academic literature. The purchases occurred without any accompanying 10b5-1 pattern, suggesting voluntary conviction.

Key Financial Metrics

Direction
buying
Total Value
$122.5K
Insiders
2

Actionable Insight

The cluster is too small to drive stock price action on its own, but CFO buying alongside a director signals management's confidence ahead of upcoming catalysts (likely TransCon PTH data or Skytrofa updates). Monitor for additional insider purchases or a material 8-K in the next 2-4 weeks. The historical calibration shows ASND insider-buy signals have underperformed (avg T+20 alpha -7.3%), so treat this as a modest positive signal, not a trade trigger.

Key Facts

  • CFO Scott Thomas purchased 350 shares total ($77.7K) across two separate open-market transactions on May 29 and June 2.
  • Director Jean-Jacques Bienaimé purchased 200 shares ($44.8K) on May 29.
  • Total cluster value of $122.5K is 0.0009% of ASND's $13.6B market cap — well below the 0.1% materiality threshold.
  • No 10b5-1 plan or vesting-driven pattern detected; both transactions are voluntary open-market buys.
  • ASND has 96% analyst bullish consensus (23 of 24 analysts at Buy/Strong Buy).

Financial Impact

Total insider purchases of $122.5K represent ~0.0009% of market cap — economically trivial in absolute terms.

insider ownership

Risk Factors

  • Historical calibration shows ASND insider-buy signals have delivered negative average alpha at T+20 (-7.3% vs SPY).
  • Dollar amount is too small to overcome the company's $13.6B market cap — institutional flows dominate.
  • No accompanying corporate event (earnings, pipeline update) to contextualize the buying.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ASND-1780431963004
14 reports for ASND
Performance horizon
78% Hit rate 7 of 9 directional calls best @ T+5▲ +13.32%Apr 7, 2026
Filters
Rows
Reports for ASND — sortable, filterable
Type Now
Jun 2, 2026
2d ago
Insider Cluster
BULLISH ★ 4/10
awaiting T+5
May 19, 2026
17d ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$237.98 $237.71▼ −0.11%▼ −2.36%$210.31 (−11.63%)
May 16, 2026
20d ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$170.74 $154.43▼ −9.55%▼ −12.99%$210.31 (+23.18%)
May 7, 2026
29d ago
6-K
BULLISH ★ 8/10
$246.14 $243.58▼ −1.04%▼ −2.54%$210.31 (−14.56%)
May 7, 2026
29d ago
6-K
BULLISH ★ 7/10
$246.14 $243.58▼ −1.04%▼ −2.54%$210.31 (−14.56%)
May 6, 2026
29d ago
Press Release
NEUTRAL ★ 5/10
$246.14 $243.58▼ −1.04%▼ −2.54%$210.31 (−14.56%)
Apr 21, 2026
6w ago
6-K
NEUTRAL ★ 3/10
$240.29 $222.08▼ −7.58%▼ −8.66%$210.31 (−12.48%)
Apr 16, 2026
7w ago
ANALYST-UPGRADE
BULLISH ★ 9/10
$242.95 $225.00▼ −7.39%▼ −8.37%$210.31 (−13.43%)
Apr 8, 2026
8w ago
6-K
NEUTRAL ★ 5/10
$241.71 $242.95▲ +0.51%▼ −2.67%$210.31 (−12.99%)
Apr 8, 2026
8w ago
6-K
BULLISH ★ 8/10
$241.71 $242.95▲ +0.51%▼ −2.67%$210.31 (−12.99%)
Showing 10 of 14

US Market Status

Market Open — Closes in 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access